The federal Food and Drug Administration is advising vaccine manufacturers to ensure new vaccines for 2024 and 2025 are targeting the KP.2 variant of COVID-19.

The agency’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously on the recommendation during a meeting earlier this month and also voted to recommend a vaccine composition that targets the virus’ JN.1 lineage.

Skip to content